News Page

Xinnate granted patent in Japan for TCP-25 formulation. The patent further strengthens the global intellectual property protection of the TCP-25 gel.

18 February, 2026

Xinnate AB har fått patent godkänt i Japan avseende formulering av TCP-25. Patentet är innebär ett ytterligare stärkt globalt immateriellt skydd för TCP-25 gelen.

18 February, 2026

Xinnate announces that recruitment has started and the first patient has been included in the STEP study with TCP-25

30 January, 2026

Xinnate meddelar att rekryteringen har startat och första patienten har blivit inkluderad i STEP-studien med TCP-25

30 January, 2026

First Scientific Publication Reporting Clinical Trial Results for Xinnate’s Proprietary Drug Candidate TCP-25

22 December, 2025

Xinnate Completes Oversubscribed Share Issue of SEK 38,5m

18 December, 2025

Xinnate Receives FDA IND Approval for TCP-25, Enabling Pivotal Phase 2/3 STEP Study in Epidermolysis Bullosa

10 December, 2025

Xinnate raises SEK 31 million in oversubscribed share issue

1 July, 2025

New Addition to Xinnate’s Board: Dr Per Norlén, MD PhD

27 June, 2025

Xinnate announces successful FDA meeting for TCP-25

23 May, 2025

EB 2026: 20-22 Jan 2026

EB Awareness week: 25-31 Oct 2025

NLS Days: 13-14 Oct 2025

ESDR MEETING: 10-13 Sep 2025